{"id":403660,"date":"2025-11-10T00:00:00","date_gmt":"2025-11-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0005-2025-biopharma-emerging-vaccines-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:26","modified_gmt":"2026-03-31T10:24:26","slug":"dlsfid0005-2026-biopharma-emerging-vaccines-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0005-2026-biopharma-emerging-vaccines-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Emerging Vaccines &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their lives to prevent infections and diseases associated with long-term chronic disorders. Given the significant advances in vaccine technologies such as <abbr title=\"messenger RNA\">mRNA<\/abbr>-based vaccines, commercial opportunity exists for robust and diverse vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccine market remain attractive for the development of new prophylactic options. This content includes coverage of key infectious diseases such as human papillomavirus (<abbr title=\"human papillomavirus\">HPV<\/abbr>), herpes zoster virus (<abbr title=\"herpes zoster\">HZ<\/abbr>), hepatitis B virus (<abbr title=\"hepatitis B virus\">HBV<\/abbr>), meningococcus, pneumococcus, seasonal influenza, respiratory syncytial virus (<abbr title=\"respiratory syncytial virus\">RSV<\/abbr>), and <abbr title=\"coronavirus disease 2019\">COVID-19<\/abbr>. Key vaccines and major market players include Pfizer (Comirnaty, Prevnar 13), GSK (Shingrix, Menveo, Arexvy), Sanofi (Fluzone, MenQuadfi), Merck (Gardasil, Pneumovax 23), and Moderna (Spikevax).<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the sizes of the populations eligible for key vaccination programs in the G7?<\/li>\n<li>What are the key drivers of brand preference in each vaccine market?<\/li>\n<li>How will the current vaccine pipeline fulfill areas of unmet need?<\/li>\n<li>How will key current and emerging vaccines perform commercially?<\/li>\n<li>In the aftermath of the <abbr title=\"coronavirus disease 2019\">COVID-19<\/abbr> pandemic, how has the use of current vaccines evolved?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><b>Primary research<\/b><strong>:<\/strong> Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Vaccine-eligible pool by country, segmented by key infectious diseases (<abbr title=\"human papillomavirus\">HPV<\/abbr>, <abbr title=\"herpes zoster\">HZ<\/abbr>, <abbr title=\"hepatitis B virus\">HBV<\/abbr>, meningococcus, pneumococcus, seasonal influenza, <abbr title=\"respiratory syncytial virus\">RSV<\/abbr>, and <abbr title=\"coronavirus disease 2019\">COVID-19<\/abbr>)<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key vaccines through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW252269907 BCX8 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-403660","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403660\/revisions"}],"predecessor-version":[{"id":575291,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/403660\/revisions\/575291"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=403660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}